ProCE Banner Activity

CME

Claudin18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

Text Module

Read this text module to learn about emerging therapies targeting claudin18.2 in gastric and gastroesophageal junction cancers.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 25, 2023

Expiration: April 24, 2024

Share

Faculty

Manish Shah

Manish Shah, MD

Chief, Solid Tumor Services
Bartlett Family Professor of Gastrointestinal Oncology
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Astellas and Bristol Myers Squibb.

Astellas

Bristol Myers Squibb

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who care for patients with gastrointestinal cancers.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in understanding of the latest science, emerging clinical trial data, and ongoing clinical trials on CLDN18.2-targeting therapies in gastric and gastroesophageal junction cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appraise the role of CLDN18.2 as a therapeutically actionable target for precision therapy in gastric and gastroesophageal junction cancers

  • Distinguish between the various constructs and mechanisms of investigational agents targeting CLDN18.2-expressed tumors

  • Evaluate emerging clinical trial evidence investigating the use of CLDN18.2-targeting agents in gastric and gastroesophageal junction cancers

  • Identify patients eligible for clinical trials investigating CLDN18.2-targeting therapies in gastric and gastroesophageal junction cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Manish Shah, MD

Chief, Solid Tumor Services
Bartlett Family Professor of Gastrointestinal Oncology
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
New York, New York

Manish A. Shah, MD: researcher: Bristol-Myers Squibb, Merck, Oncolys BioPharma.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 25, 2023, through April 24, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.